Daily Endocrinology Research Analysis
Three impactful studies span mechanistic metabolism, public health screening, and rare genetic disorders intersecting with metabolic biology. A Nature Cell Biology paper uncovers a chaperone-driven mechanism inserting TOM70 into the outer mitochondrial membrane to boost thermogenesis and protect against diet-induced obesity. The EDENT1FI Master Protocol standardizes presymptomatic type 1 diabetes screening across eight European countries, while an AJHG study defines EEFSEC deficiency as a seleno
Summary
Three impactful studies span mechanistic metabolism, public health screening, and rare genetic disorders intersecting with metabolic biology. A Nature Cell Biology paper uncovers a chaperone-driven mechanism inserting TOM70 into the outer mitochondrial membrane to boost thermogenesis and protect against diet-induced obesity. The EDENT1FI Master Protocol standardizes presymptomatic type 1 diabetes screening across eight European countries, while an AJHG study defines EEFSEC deficiency as a selenopathy with mechanistic validation.
Research Themes
- Mitochondrial proteostasis and thermogenic energy metabolism
- Early detection and disease interception in type 1 diabetes
- Selenoprotein biology and neurodegeneration
Selected Articles
1. Chaperone-mediated insertion of mitochondrial import receptor TOM70 protects against diet-induced obesity.
This mechanistic study shows that the stress-induced chaperone PPID inserts TOM70 into the outer mitochondrial membrane, enhancing brown adipocyte respiration and thermogenesis. In obese mice, this mechanism protects body temperature regulation and mitigates weight gain, revealing an ER-stress–activated chaperone route for tuning energy metabolism.
Impact: It uncovers a previously unrecognized chaperone-dependent control point in mitochondrial protein insertion that directly affects thermogenesis and obesity risk. This provides a mechanistic basis for new anti-obesity targets beyond classical hormonal pathways.
Clinical Implications: Although preclinical, targeting PPID–TOM70 insertion or its regulatory domains may offer novel strategies to boost adaptive thermogenesis in obesity and metabolic syndrome.
Key Findings
- PPID drives outer mitochondrial membrane insertion of TOM70 via its PPIase activity and C-terminal TPR domains.
- Enhancing TOM70 insertion improves brown adipocyte respiratory/thermogenic function.
- In obese mice, the PPID–TOM70 pathway modulates body temperature and weight under cold and high-calorie conditions.
Methodological Strengths
- Rigorous multi-level mechanistic approach combining in vivo obese mouse models and brown adipocyte functional assays
- Domain-specific mapping of PPID–TOM70 interactions to define causality
Limitations
- Preclinical model without human validation
- Safety and on-target specificity of manipulating PPID activity remain untested clinically
Future Directions: Validate PPID–TOM70 modulation in human adipocytes and delineate druggable nodes; assess cardio-metabolic safety and efficacy in higher organisms.
Outer mitochondrial membrane (OMM) proteins communicate with the cytosol and other organelles, including the endoplasmic reticulum. This communication is important in thermogenic adipocytes to increase the energy expenditure that controls body temperature and weight. However, the regulatory mechanisms of OMM protein insertion are poorly understood. Here the stress-induced cytosolic chaperone PPID (peptidyl-prolyl isomerase D/cyclophilin 40/Cyp40) drives OMM insertion of the mitochondrial import receptor TOM70 that regulates body temperature and weight in obese mice, and respiratory/thermogenic function in brown adipocytes. PPID PPIase activity and C-terminal tetratricopeptide repeats, which show specificity towards TOM70 core and C-tail domains, facilitate OMM insertion.
2. EEFSEC deficiency: A selenopathy with early-onset neurodegeneration.
Across nine individuals from eight families, bi-allelic EEFSEC variants cause a selenoprotein deficiency syndrome with early-onset progressive neurodegeneration dominated by cerebellar pathology. Functional assays in fibroblasts and an eEFSec-RNAi Drosophila model validate reduced selenoprotein synthesis and link the genotype to synaptic and motor dysfunction.
Impact: Defines a new inborn error of selenocysteine metabolism with strong mechanistic validation, expanding human selenoprotein biology relevant to metabolic and endocrine pathways.
Clinical Implications: Enables genetic diagnosis and counseling for selenopathy; suggests exploring targeted metabolic support (e.g., selenium status, antioxidant pathways) while future therapies could modulate selenoprotein synthesis.
Key Findings
- Six distinct bi-allelic EEFSEC variants identified in nine individuals cause a recessive selenoprotein deficiency disorder.
- Patient fibroblasts show reduced selenoprotein levels, confirming impaired EEFSEC function.
- An eEFSec-RNAi Drosophila model recapitulates progressive motor and synaptic defects, aligning with human cerebellar-dominant pathology.
Methodological Strengths
- Integration of human genetics with in vitro functional assays and an in vivo Drosophila model
- Consistent clinical-radiologic phenotype with mechanistic validation of the causal pathway
Limitations
- Small sample size inherent to rare disease case series
- Limited therapeutic data; interventional strategies remain speculative
Future Directions: Elucidate tissue-specific selenoprotein deficits and test metabolic or gene-based interventions in models; establish natural history to inform trial endpoints.
Inborn errors of selenoprotein expression arise from deleterious variants in genes encoding selenoproteins or selenoprotein biosynthetic factors, some of which are associated with neurodegenerative disorders. This study shows that bi-allelic selenocysteine tRNA-specific eukaryotic elongation factor (EEFSEC) variants cause selenoprotein deficiency, leading to progressive neurodegeneration. EEFSEC deficiency, an autosomal recessive disorder, manifests with global developmental delay, progressive spasticity, ataxia, and seizures. Cerebral MRI primarily demonstrated a cerebellar pathology, including hypoplasia and progressive atrophy. Exome or genome sequencing identified six different bi-allelic EEFSEC variants in nine individuals from eight unrelated families. These variants showed reduced EEFSEC function in vitro, leading to lower levels of selenoproteins in fibroblasts. In line with the clinical phenotype, an eEFSec-RNAi Drosophila model displays progressive impairment of motor function, which is reflected in the synaptic defects in this model organisms. This study identifies EEFSEC deficiency as an inborn error of selenocysteine metabolism. It reveals the pathophysiological mechanisms of neurodegeneration linked to selenoprotein metabolism, suggesting potential targeted therapies.
3. EDENT1FI Master Protocol for screening of presymptomatic early-stage type 1 diabetes in children and adolescents.
The EDENT1FI Master Protocol harmonizes islet autoantibody screening and metabolic staging for presymptomatic type 1 diabetes across eight European countries, targeting ~200,000 children and adolescents by 2028. Standardized confirmation, education, and registry-based follow-up aim to reduce DKA at diagnosis and enable disease interception.
Impact: This coordinated, large-scale screening infrastructure can shift clinical practice by enabling early detection and standardized care pathways for stage 1–2 type 1 diabetes.
Clinical Implications: If implemented widely, pediatric screening and follow-up could reduce DKA at onset, lower acute healthcare utilization, and create pathways for preventative immunotherapy trials.
Key Findings
- Master Protocol standardizes islet autoantibody screening, confirmation, and metabolic staging across eight countries.
- Target enrollment is ~200,000 children/adolescents aged 1–17 years (2023–2028).
- Registry-based follow-up and acceptability assessments aim to evaluate feasibility, DKA reduction, and care outcomes.
Methodological Strengths
- Prospective, multicountry, standardized screening and staging with ethics approvals and registry integration
- Clear confirmatory workflows (second method, venous sample) to reduce false positives
Limitations
- Protocol paper without outcomes; effectiveness and cost-effectiveness remain to be demonstrated
- Heterogeneity in healthcare systems may impact harmonized implementation
Future Directions: Report screening yield, DKA rates, and psychosocial outcomes; evaluate cost-effectiveness and pathways to implement preventative interventions for stage 2–3 conversion delay.
INTRODUCTION: The identification of type 1 diabetes at an early presymptomatic stage has clinical benefits. These include a reduced risk of diabetic ketoacidosis (DKA) at the clinical manifestation of the disease and a significant reduction in clinical symptoms. The European action for the Diagnosis of Early Non-clinical Type 1 diabetes For disease Interception (EDENT1FI) represents a pioneering effort to advance early detection of type 1 diabetes through public health screening. With the EDENT1FI Master Protocol, the project aims to harmonise and standardise screening for early-stage type 1 diabetes and care. METHODS AND ANALYSIS: Public health islet autoantibody screening is conducted in the Czech Republic, Denmark, Germany, Italy, Poland, Portugal, Sweden and the UK. Between November 2023 (start date) and October 2028 (planned end date), an estimated number of 200 000 children and adolescents aged 1-17 years are expected to be screened.